Table 1 General characteristics of the population, outcome, and type of sepsis

Male (n; %)

108; 52%

21; 60%

87; 51%

Age (years), med (IQR)

63 (52–73)

67 (62–77)

63 (51–72)

Weight (kg), med (IQR)

75 (64–90)

70 (60–86)

78 (65–90)

Statin (n; %)

63; 31%

8; 22%

55; 32%

Septic shock (n; %)

149; 73%

33; 22%

116; 78%

Severe sepsis (n; %)

56; 27%

2; 4%

54; 96%

Bacteremia (n; %)

53; 26%

12; 23%

41; 77%

Intra-abdominal sepsis (n; %)

87; 42%

16; 18%

71; 82%

Pleuropulmonary sepsis (n; %)

29; 14%

6; 21%

23; 79%

Urinary tract infections (n; %)

35; 17%

3; 9%

32; 91%

Skin and soft tissue infections (n; %)

35; 17%

8; 23%

27; 77%

Other sepsis (n; %)

19; 10%

2; 11%

17; 89%

KDIGO AKI stage max, med (IQR)

1 (0–3)

3 (2–3)

1 (0–2)

SAPSII score day 1, med (IQR)

57 (40–68)

75 (64–89)

54 (38–63)

SOFA day 1, med (IQR)

7 (4–9)

10 (7–12)

6 (4–8)

Lactate day 1 (mmol/l), med (IQR)

2.2 (1.4–3.4)

3.0 (2.0–5.3)

2.1 (1.3–3.3)

Norepinephrine day 1 (micg/kg/min), med (IQR)

0.23 (0.0–0.55)

0.66 (0.48–1.24)

0.18 (0–0.41)

RRT day 1 (n; %)

22; 11%

9; 26%

13; 8%

SOFA day 3, med (IQR)

4 (1–7)

11 (7–13)

3 (1–6)

Lactate day 3 (mmol/l), med (IQR)

1.4 (1.0–1.9)

2.4 (1.8–6.9)

1.3 (0.9–1.8)

Norepinephrine day 3 (micg/kg/min), med (IQR)

0.0 (0.0–0.24)

0.48 (0.25–0.91)

0.0 (0.0- 0.1)

RRT day 3 (n; %)

25; 12%

12; 34%

13; 8%

Length of stay in ICU (days), med (IQR)

7 (3–16)

6 (3–13)

7 (4–17)

Length of mechanical ventilation (days), med (IQR)

2 (0–8)

5 (2–12)

2 (0–7)

Days alive without MV at D28, med (IQR)

26 (11–28)

0 (0–2)

26 (21–28)